ArticleBiomarker research2014

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.

Naoto Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.